10-KPeriod: FY2022

DEXCOM INC Annual Report, Year Ended Dec 31, 2022

Filed February 9, 2023For Securities:DXCM

Summary

DexCom, Inc. (DXCM) reported strong performance in its 2022 10-K filing, highlighting significant revenue growth driven by increased sales volume of its disposable sensors. The company launched its latest generation continuous glucose monitoring (CGM) system, the Dexcom G7®, in December 2022, following FDA clearance, which is expected to further enhance its market position. Financially, Dexcom demonstrated robust growth with a 19% increase in revenue to $2.91 billion and a 57% rise in net income to $341.2 million. The company ended the year with a strong liquidity position, boasting $2.46 billion in cash, cash equivalents, and marketable securities. Dexcom continues to focus on product innovation, expanding market access, and strategic partnerships, particularly in the diabetes management ecosystem, positioning itself for continued growth in the expanding CGM market.

Financial Highlights

53 data points
Beta

Revenue

$2.91B

64.7% Gross Margin

Net Income

$341.20M

11.7% Net Margin

EPS (Diluted)

$0.82

Total Assets

$5.39B

Cash & Equivalents

$643.30M

Free Cash Flow

$304.70M

Financial Statements
Beta
Revenue$2.91B
Cost of Revenue$1.03B
Gross Profit$1.88B
R&D Expenses$484.20M
SG&A Expenses$1.01B
Operating Expenses$1.49B
Operating Income$391.20M
Interest Expense$14.70M
Net Income$341.20M
EPS (Basic)$0.88
EPS (Diluted)$0.82
Shares Outstanding (Basic)389.40M
Shares Outstanding (Diluted)427.50M

Key Highlights

  • 1Revenue increased by 19% year-over-year to $2.91 billion, driven by strong sales volume of disposable CGM sensors.
  • 2Net income saw a substantial increase of 57% to $341.2 million, demonstrating improved profitability.
  • 3The company launched its latest generation CGM system, Dexcom G7®, in December 2022, following FDA marketing clearance, enhancing its product portfolio.
  • 4Dexcom ended the fiscal year with a strong liquidity position, holding $2.46 billion in cash, cash equivalents, and marketable securities.
  • 5Operating income grew by 47% to $391.2 million, reflecting improved operational efficiency.
  • 6Dexcom continues to invest in R&D, with a focus on future product development and intelligent insulin administration integration.
  • 7A share repurchase program of up to $700 million was authorized, indicating a commitment to returning value to shareholders.

Frequently Asked Questions

Dexcom is a medical device company focused on designing, developing, and commercializing continuous glucose monitoring (CGM) systems for people with diabetes. The company reported strong financial performance in 2022, with revenue growing 19% to $2.91 billion and net income increasing 57% to $341.2 million, driven by increased sales volume of its disposable sensors.

Dexcom's primary products are the Dexcom G6® and the newly launched Dexcom G7® integrated Continuous Glucose Monitoring Systems. The G7, which received FDA marketing clearance in December 2022, offers improved features such as a smaller size, faster warm-up time, and enhanced discretion compared to previous generations.

Dexcom maintains a strong financial position, ending 2022 with $2.46 billion in cash, cash equivalents, and marketable securities. The company generated $669.5 million in operating cash flow for the year and had no outstanding borrowings under its credit facility as of December 31, 2022, indicating robust liquidity and financial stability.

Key risks for Dexcom include intense competition from established medical device companies, potential pricing pressures from third-party payors, reliance on third-party suppliers, and the complex regulatory environment for medical devices. Additionally, the company faces risks associated with product development timelines, cybersecurity, and potential changes in healthcare policies and reimbursement.